Drug Profile

Tandospirone ophthalmic

Alternative Names: AL-8309; AL-8309A; AL-8309B

Latest Information Update: 02 Oct 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Alcon
Class Anxiolytics; Eye disorder therapies; Isoindoles; Piperazines; Pyrimidines
Mechanism of Action 5-HT1A serotonin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Discontinued Dry macular degeneration

Most Recent Events

09 Apr 2019 Novartis completed the spin-off of Alcon
07 Nov 2011 AL 8309B is still in phase III development for geographic atrophy secondary to Age-related macular degeneration in USA
08 Apr 2011 Novartis completes acquisition of Alcon

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com